BioSante to Present LibiGel Data at ISSWSH Meeting.

LINCOLNSHIRE, Ill. -- Results to Detail Positive Impact of Testosterone Gel on Number of Satisfying Sexual Events in Women with Female Sexual Dysfunction 

BioSante Pharmaceuticals, Inc. (Amex:BPA) today announced that new clinical data on LibiGel(TM), an investigational transdermal testosterone gel, will be presented at the International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting in Atlanta (October 28-31). Results demonstrating the benefit of LibiGel in surgically menopausal women suffering from female sexual dysfunction (FSD) will be presented during an oral presentation to take place on Saturday, October 30 at 10:44 a.m.

The paper, entitled "Efficacy and Safety of LibiGel(TM) - A Novel Testosterone Gel for Decreased Sexual Desire" (Abstract #28, Podium #32), will be presented during the meeting's oral Paper Session #4 by James A. Simon, M.D., Clinical Professor of Obstetrics and Gynecology, George Washington University, Washington, D.C.; Medical Director, Women's Health Research Center, Laurel, Maryland; President, North American Menopause Society and lead investigator of the study.

BioSante will hold a conference call for investors on Monday, November 1, 2004 at 8:30 a.m. ET. To participate, dial toll-free [phone]. To access the live broadcast in listen-only mode, please visit: http://www.vcall.com/CEPage.asp?ID=89677, which will be available until February 1, 2005.

About BioSante's Hormone Product Portfolio

In addition to LibiGel, BioSante is developing Bio-T-Gel(TM) for treatment of men with testosterone deficiency and Bio-E-Gel(TM) for treatment of women with menopausal symptoms. Symptoms of these hormone deficiencies in men include impotence, diminished sex drive, muscle weakness and osteoporosis. Symptoms in menopausal women include hot flashes, vaginal atrophy, decreased libido and osteoporosis. The transdermal gel formulations used in the female gel products are licensed by BioSante from Antares Pharma Inc. (Amex: AIS). The estrogen and testosterone markets in the United States alone account for approximately $2.5 billion in annual sales.

About BioSante Pharmaceuticals, Inc.

BioSante is developing a pipeline of hormone therapy products to treat both men and women. BioSante's hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. The company also is developing its calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Additional information is available online at www.biosantepharma.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this press release that are not historical in nature, particularly those that utilize terminology such as "may," "will," "should," "likely," "expects," "anticipates, " "estimates," "believes" or "plans," or comparable terminology, are forward-looking statements. Forward- looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that cause actual results to differ materially from those expressed in such forward-looking statements are the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, and other factors identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors discussed on pages 18 to 25 of BioSante's Form 10-KSB, which discussion also is incorporated herein by reference.